# Acute Exacerbations Treated With BenRAlizumab (The ABRA Study)

> **NCT04098718** · PHASE2 · UNKNOWN · sponsor: **University of Oxford** · enrollment: 158 (estimated)

## Conditions studied

- Asthma
- COPD

## Interventions

- **DRUG:** Benralizumab
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT04098718
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-29
- **Primary completion:** 2024-02-19
- **Final completion:** 2024-11-19
- **Target enrollment:** 158 (ESTIMATED)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04098718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04098718, "Acute Exacerbations Treated With BenRAlizumab (The ABRA Study)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04098718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*